NCT06416995

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

Name: Clinical Trial NCT06416995
Creator: Umraniye Education and Research Hospital
Keywords: Preeclampsia,Gestational Hypertension,Gestational Diabetes,Preterm Birth,Fetal Growth Retardation, first trimester serum diagnostic test, diagnostic test, clinical trial, Turkey

Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes

Umraniye Education and Research Hospital·ClinicalTrials.gov·diagnostic testRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Preeclampsia,Gestational Hypertension,Gestational Diabetes,Preterm Birth,Fetal Growth Retardation
Drug/Device/Intervention: first trimester serum diagnostic test
Study type: Observational
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Umraniye Education and Research Hospital
Location: Istanbul, Turkey

Timeline & enrollment

Phase: N/A
Start date: Mar 03, 2023
End date: Dec 30, 2024
Enrollment: 88 participants

Primary outcome

Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes

Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

ICD-10 classifications

Gestational [pregnancy-induced] hypertensionFetus and newborn affected by maternal hypertensive disordersUnspecified maternal hypertensionDisorders related to length of gestation and fetal growthNeonatal hypertension

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06416995
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06416995 through Pure Global AI's free database. This phase not specified trial is sponsored by Umraniye Education and Research Hospital and is currently Recruiting. The study focuses on Preeclampsia,Gestational Hypertension,Gestational Diabetes,Preterm Birth,Fetal Growth Retardation. Target enrollment is 88 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.